MedTrace Logo

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

NCT03003494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 306

Last updated 2019-09-30

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Spiolto® Respimat®

observations taken in a period of approximately 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2018-07-30
Completion
2018-07-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003494 on ClinicalTrials.gov